Longevity Acquisition completed a merger with 4D Pharma in a $26.1m deal.

Longevity Acquisition, a special purposes acquisition company, completed a merger with 4D Pharma, a pharmaceutical company, in a $26.1m deal. 4D pharma American Depositary Shares (“ADSs”) are expected to begin trading today on the Nasdaq Global Market under the ticker symbol ‘LBPS.’ "The closing of 4D pharma’s merger with Longevity represents a transformational milestone for the Company. Becoming a dual-listed company both in the UK and the US broadens our global reach. In conjunction with the NASDAQ listing, the closing of the Merger and concurrent fundraise give 4D pharma an additional $40 million of capital and puts the Company in a very strong financial position to execute across our robust pipeline," Duncan Peyton, 4D Pharma CEO.